"Unity in strength" is a notion that can be exploited to characterize biofilms as they bestow microbes with protection to live freely, escalate their virulence, confer high resistance to therapeutic agents, and provide active grounds for the production of biofilms after dispersal. Naturally, fungal biofilms are inherently resistant to many conventional antifungals, possibly owing to virulence factors as their ammunitions that persistently express amid planktonic transition to matured biofilm state. These ammunitions include the ability to form polymicrobial biofilms, emergence of persister cells post-antifungal treatment and acquisition of resistance genes. One of the major disorders affecting vaginal health is vulvovaginal candidiasis (VVC) and its reoccurrence is termed recurrent VVC (RVVC). It is caused by the species which include and . The aforementioned species, notably is a biofilm producing pathogen and habitually forms part of the vaginal microbiota of healthy women. Latest research has implicated the role of fungal biofilms in VVC, particularly in the setting of treatment failure and RVVC. Consequently, a plethora of studies have advocated the utilization of probiotics in addressing these infections. Specifically, the excreted or released compounds of probiotics which are also known as postbiotics are being actively researched with vast potential to be used as therapeutic options for the treatment and prevention of VVC and RVVC. These potential sources of postbiotics are harnessed due to their proven antifungal and antibiofilm. Hence, this review discusses the role of biofilm formation in VVC and RVVC. In addition, we discuss the application of pro-, pre-, post-, and synbiotics either individually or in combined regimen to counteract the abovementioned problems. A clear understanding of the role of biofilms in VVC and RVVC will provide proper footing for further research in devising novel remedies for prevention and treatment of vaginal fungal infections.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9179178 | PMC |
| http://dx.doi.org/10.3389/fmicb.2022.787119 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Highlight signatures of vaginal microbiota and metabolome contributed to the occurrence and recurrence of vulvovaginal candidiasis.
Microbiol Spectr
October 2024
Center of Obstetrics and Gynecology, Peking University Shenzhen Hospital, Shenzhen, China.
Article Synopsis
- Vulvovaginal candidiasis (VVC) is a common infection with a high recurrence rate, defined as having four or more episodes in a year, which poses significant clinical challenges.
- In this study, researchers analyzed vaginal samples from 31 recurrent VVC patients, 28 VVC patients, and 29 healthy women, finding similarities in symptoms but noting increased swelling in the VVC group.
- The analysis revealed changes in the vaginal microbiota, including decreased beneficial bacteria and increased bacteria associated with bacterial vaginosis, highlighting the potential role of metabolites like L-glutamate in recurring infections, which may inform future treatment strategies.
Host-microbe interaction paradigms in acute and recurrent vulvovaginal candidiasis.
Cell Host Microbe
October 2024
Fungal Pathogenesis Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy & Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. Electronic address:
Article Synopsis
- * About 5-10% of women who experience VVC develop recurrent VVC (RVVC), and the review highlights factors influencing susceptibility to these conditions, including immune dysfunction.
- * The authors emphasize the need for more research to understand the immune responses involved, aiming to improve prevention, treatment, and potential vaccination strategies against these infections.
Plasma Inflammatory Proteome Profile in a Cohort of Patients with Recurrent Vulvovaginal Candidiasis in Kenya.
J Fungi (Basel)
September 2024
Department of Internal Medicine, Radboud Center for Infectious Diseases, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.
Article Synopsis
- - Vulvovaginal candidiasis (VVC) impacts up to 75% of women, with roughly 8% experiencing frequent recurrent cases (RVVC), due to host response issues and excessive inflammation.
- - The study examined inflammatory protein levels in 158 RVVC patients and 92 healthy women, using advanced technology to analyze 92 different proteins, without finding significant links to hormonal contraceptive use.
- - RVVC patients showed lower levels of Fibroblast Growth Factor 21 (FGF-21), a potential marker for immune issues related to RVVC, highlighting the possibility of developing new diagnostic tools and treatments.
Probiotics in the Management of Vulvovaginal Candidosis.
J Clin Med
August 2024
Femicare, Clinical Research for Women, 3300 Tienen, Belgium.
Article Synopsis
- Vulvovaginal candidosis (VVC) is a common and troublesome vaginal infection, and many patients experience recurrent cases even after antifungal treatment.
- Probiotics may serve as a useful alternative or complementary treatment option for managing VVC, as studies suggest they could improve patient outcomes, even though current findings on their effectiveness are mixed.
- The research indicates that while antifungals like fluconazole are still more effective, combining them with probiotics could help reduce recurrence and improve symptoms, prompting a need for more targeted future studies on probiotics' roles in VVC treatment and prevention.
Inflammatory cytokine signalling in vulvovaginal candidiasis: a hot mess driving immunopathology.
Oxf Open Immunol
August 2024
Junior Research Group Adaptive Pathogenicity Strategies, Leibniz Institute for Natural Product Research and Infection Biology, Hans Knöll Institute (Leibniz-HKI), Beutenbergstraße 11a, Jena, 07749, Germany.
Protective immunity to opportunistic fungal infections consists of tightly regulated innate and adaptive immune responses that clear the infection. Immune responses to infections of the vaginal mucosa by species are, however, an exception. In the case of vulvovaginal candidiasis (VVC), the inflammatory response is associated with symptomatic disease, rather than that it results in pathogen clearance.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!